Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Myeloid translocation gene CBFA2T3 directs a relapse gene program and determines patient-specific outcomes in AML.

Steinauer N, Guo C, Huang C, Wong M, Tu Y, Freter CE, Zhang J.

Blood Adv. 2019 May 14;3(9):1379-1393. doi: 10.1182/bloodadvances.2018028514.

2.

Oolong Tea Extract Induces DNA Damage and Cleavage and Inhibits Breast Cancer Cell Growth and Tumorigenesis.

Shi H, Liu J, Tu Y, Freter CE, Huang C.

Anticancer Res. 2018 Nov;38(11):6217-6223. doi: 10.21873/anticanres.12976.

PMID:
30396940
3.

Fludarabine-resistance associates with ceramide metabolism and leukemia stem cell development in chronic lymphocytic leukemia.

Huang C, Tu Y, Freter CE.

Oncotarget. 2018 Sep 4;9(69):33124-33137. doi: 10.18632/oncotarget.26043. eCollection 2018 Sep 4.

4.

Acute myeloid leukemia induction with cladribine: Outcomes by age and leukemia risk.

Schoen MW, Woelich SK, Braun JT, Reddy DV, Fesler MJ, Petruska PJ, Freter CE, Lionberger JM.

Leuk Res. 2018 May;68:72-78. doi: 10.1016/j.leukres.2018.03.005. Epub 2018 Mar 6.

PMID:
29574395
5.

Efficacy and Toxicity of Induction Therapy with Cladribine, Idarubicin, and Cytarabine (IAC) for Acute Myeloid Leukemia.

Woelich SK, Braun JT, Schoen MW, Ramlal R, Freter CE, Petruska PJ, Lionberger JM.

Anticancer Res. 2017 Feb;37(2):713-717.

PMID:
28179321
6.

Signaling regulation and role of filamin A cleavage in Ca2+-stimulated migration of androgen receptor-deficient prostate cancer cells.

Huang C, Miller RT, Freter CE.

Oncotarget. 2017 Jan 17;8(3):3840-3853. doi: 10.18632/oncotarget.9472.

7.

Thromboprophylaxis and Incidence of Venous Thromboembolism in Patients With Hemophilia A or B Who Underwent High-Risk Orthopedic Surgeries.

Raza S, Kale G, Kim D, Akbar SA, Holm L, Naidzionak U, Hossain AM, Dong X, Doll DC, Freter CE, Hopkins T.

Clin Appl Thromb Hemost. 2016 Mar;22(2):161-5. doi: 10.1177/1076029614543139. Epub 2014 Jul 9.

PMID:
25008348
8.

Anti-tumor monoclonal antibodies in conjunction with β-glucans: a novel anti-cancer immunotherapy.

Xiang D, Sharma VR, Freter CE, Yan J.

Curr Med Chem. 2012;19(25):4298-305. Review.

PMID:
22834812
9.

Iron deficiency anemia related to hereditary hemorrhagic telangiectasia: response to treatment with bevacizumab.

Fleagle JM, Bobba RK, Kardinal CG, Freter CE.

Am J Med Sci. 2012 Mar;343(3):249-51. doi: 10.1097/MAJ.0b013e3182429866.

PMID:
22227516
10.

Plasma microRNAs as novel biomarkers for early detection of lung cancer.

Zheng D, Haddadin S, Wang Y, Gu LQ, Perry MC, Freter CE, Wang MX.

Int J Clin Exp Pathol. 2011 Aug 15;4(6):575-86. Epub 2011 Aug 8.

11.

Postoperative bleeding in an elderly patient from acquired factor V inhibitor: rapid response to immunosuppressive therapy.

Bobba RK, Garg P, Arya M, Freter CE.

Am J Med Sci. 2011 Mar;341(3):253-6. doi: 10.1097/MAJ.0b013e31820375be. Review.

PMID:
21289509
12.

Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine.

Rai KR, Freter CE, Mercier RJ, Cooper MR, Mitchell BS, Stadtmauer EA, Santábarbara P, Wacker B, Brettman L.

J Clin Oncol. 2002 Sep 15;20(18):3891-7.

PMID:
12228210
13.

Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.

Lee EJ, Petroni GR, Schiffer CA, Freter CE, Johnson JL, Barcos M, Frizzera G, Bloomfield CD, Peterson BA.

J Clin Oncol. 2001 Oct 15;19(20):4014-22. Review.

PMID:
11600602
14.

Intravascular large cell lymphoma coexisting within hemangiomas of the skin.

Rubin MA, Cossman J, Freter CE, Azumi N.

Am J Surg Pathol. 1997 Jul;21(7):860-4.

PMID:
9236844
15.

Hodgkin's disease treated with neck radiation is associated with increased antibody-dependent cellular cytotoxicity against human extraocular muscle cells.

Ringel MD, Taylor T, Barsouk A, Wall JR, Freter CE, Howard RS, Diehl L, Burman KD.

Thyroid. 1997 Jun;7(3):425-32.

PMID:
9226215
16.

Mechanisms of inhibition of IL-6-mediated immunoglobulin secretion by dexamethasone and suramin in human lymphoid and myeloma cell lines.

Shiao RT, McLeskey SB, Khera SY, Wolfson A, Freter CE.

Leuk Lymphoma. 1996 Apr;21(3-4):293-303.

PMID:
8726410
17.
18.

Angioimmunoblastic lymphadenopathy with dysproteinemia.

Freter CE, Cossman J.

Semin Oncol. 1993 Dec;20(6):627-35. Review. No abstract available.

PMID:
8296199
19.

Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo.

Strassmann G, Fong M, Freter CE, Windsor S, D'Alessandro F, Nordan RP.

J Clin Invest. 1993 Nov;92(5):2152-9.

20.

High circulating interleukin 6 levels associated with acute transfusion reaction: cause or effect?

Sacher RA, Boyle L, Freter CE.

Transfusion. 1993 Nov-Dec;33(11):962-3. No abstract available.

PMID:
8110277
21.
22.
23.

Acquired immunodeficiency syndrome-associated lymphomas.

Freter CE.

J Natl Cancer Inst Monogr. 1990;(10):45-54. Review.

PMID:
2189476
24.

Phosphoinositide metabolism in human prostate cancer cells in vitro.

Wilding G, Gelmann EP, Freter CE.

Prostate. 1990;16(1):15-27.

PMID:
2154736
25.

Expression of transforming growth factor alpha and its messenger ribonucleic acid in human breast cancer: its regulation by estrogen and its possible functional significance.

Bates SE, Davidson NE, Valverius EM, Freter CE, Dickson RB, Tam JP, Kudlow JE, Lippman ME, Salomon DS.

Mol Endocrinol. 1988 Jun;2(6):543-55.

PMID:
3047554
26.

Alterations in phosphoinositide metabolism associated with 17 beta-estradiol and growth factor treatment of MCF-7 breast cancer cells.

Freter CE, Lippman ME, Cheville A, Zinn S, Gelmann EP.

Mol Endocrinol. 1988 Feb;2(2):159-66.

PMID:
2840572
27.

Translocation t(11;22) in esthesioneuroblastoma.

Whang-Peng J, Freter CE, Knutsen T, Nanfro JJ, Gazdar A.

Cancer Genet Cytogenet. 1987 Nov;29(1):155-7.

PMID:
3478125
28.

Doxorubicin cardiac toxicity manifesting seven years after treatment. Case report and review.

Freter CE, Lee TC, Billingham ME, Chak L, Bristow MR.

Am J Med. 1986 Mar;80(3):483-5.

PMID:
3513562
29.

Conditions influencing formation of 16:0/16:0 molecular species in membrane phospholipids of Escherichia coli.

Lau C, Greenway DL, Freter CE, Neungton N, Wattenberg B, Silbert DF.

J Biol Chem. 1983 Nov 10;258(21):13027-33.

30.

Effect of membrane sterol content on the susceptibility of phospholipids to phospholipase A2.

Fisher GJ, Freter CE, Ladenson RC, Silbert DF.

J Biol Chem. 1983 Oct 10;258(19):11705-12.

31.

Sterol depletion of LM cells using chemical inhibitors and genetic defects. A comparison of secondary phospholipid alterations.

Wattenberg BW, Freter CE, Silbert DF.

J Biol Chem. 1979 Dec 25;254(24):12295-8. No abstract available.

32.

Membrane phospholipid alterations in response to sterol depletion of LM cells. Metabolic studies.

Freter CE, Ladenson RC, Silbert DF.

J Biol Chem. 1979 Aug 10;254(15):6909-16. No abstract available.

Supplemental Content

Loading ...
Support Center